Literature DB >> 11850139

Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels.

Sara Gonzalez1, Javier Fernandez-Ruiz, Valentina Sparpaglione, Daniela Parolaro, Jose A Ramos.   

Abstract

Recent evidence suggest that the endocannabinoid system might be a component of the brain reward system and, then, play a role, not only in cannabinoid tolerance/dependence, but also in dependence/withdrawal to other drugs of abuse. However, there are not many studies that compare the changes in endocannabinoid ligands and/or receptors in brain regions (particularly in those areas related to reinforcement processes) during dependence to opiates, cocaine or alcohol. The present study addressed this objective, by examining the changes in CB(1) receptor binding (measured by [3H]-CP55,940 autoradiography) and its mRNA levels (measured by in situ hybridization) in different brain regions of animals chronically exposed to morphine, cocaine or ethanol. The results showed that these three drugs produced different changes in CB(1) receptor binding and mRNA levels, a finding that precludes the existence of a common alteration of the endocannabinoid system during dependence states to these habit-forming drugs. Thus, chronic ethanol exposure was usually uneffective in altering both CB(1) receptor binding and mRNA levels in all regions examined. In contrast, chronic cocaine exposure produced significant changes only at the level of CB(1) receptor mRNA, with decreases of the transcript levels in the ventromedial hypothalamic nucleus and the superficial and deep layers of the cerebral cortex, but no changes in the hippocampal, motor and limbic structures. Finally, chronic morphine exposure increased the density of CB(1) receptors in the medial caudate-putamen, but decreased their mRNA levels in this region and also in the lateral caudate-putamen and the cerebellum. In limbic structures, chronic morphine exposure increased both binding and mRNA levels for CB(1) receptors in the septum nuclei. Binding was also increased in the nucleus accumbens, but reduced in the basolateral amygdala. In hippocampal structures, chronic morphine exposure reduced CB(1) receptor binding in the dentate gyrus, although mRNA levels were unaffected in this region, but increased in the CA2 subfield of the Ammon's horn. The results indicate that mechanisms of dependence for alcohol, cocaine and morphine are different in terms of their impact on the endocannabinoid system. Alcohol did not produce any effects on CB(1) receptor binding and mRNA levels, whereas cocaine only affected transcript levels in selected regions and morphine produced divergent and region-dependent effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850139     DOI: 10.1016/s0376-8716(01)00186-7

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  38 in total

1.  Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography.

Authors:  J Hirvonen; P Zanotti-Fregonara; J C Umhau; D T George; D Rallis-Frutos; C H Lyoo; C-T Li; C S Hines; H Sun; G E Terry; C Morse; S S Zoghbi; V W Pike; R B Innis; M Heilig
Journal:  Mol Psychiatry       Date:  2012-07-10       Impact factor: 15.992

2.  Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats.

Authors:  K Yaragudri Vinod; Paola Maccioni; Maria Salud Garcia-Gutierrez; Teresa Femenia; Shan Xie; Mauro A M Carai; Jorge Manzanares; Thomas B Cooper; Basalingappa L Hungund; Giancarlo Colombo
Journal:  Addict Biol       Date:  2011-02-11       Impact factor: 4.280

Review 3.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 4.  Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls.

Authors:  Matthew W Buczynski; Loren H Parsons
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Intra-accumbal Cannabinoid Agonist Attenuated Reinstatement but not Extinction Period of Morphine-Induced Conditioned Place Preference; Evidence for Different Characteristics of Extinction Period and Reinstatement.

Authors:  Hossein Khaleghzadeh-Ahangar; Abbas Haghparast
Journal:  Neurochem Res       Date:  2017-08-05       Impact factor: 3.996

6.  Health Disparities in Drug- and Alcohol-Use Disorders: A 12-Year Longitudinal Study of Youths After Detention.

Authors:  Leah J Welty; Anna J Harrison; Karen M Abram; Nichole D Olson; David A Aaby; Kathleen P McCoy; Jason J Washburn; Linda A Teplin
Journal:  Am J Public Health       Date:  2016-03-17       Impact factor: 9.308

7.  Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol.

Authors:  Marina Rubio; Douglas McHugh; Javier Fernández-Ruiz; Heather Bradshaw; J Michael Walker
Journal:  Neurosci Lett       Date:  2007-06-02       Impact factor: 3.046

8.  Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.

Authors:  Daniela Viganò; Tiziana Rubino; Angelo Vaccani; Silvia Bianchessi; Patrick Marmorato; Chiara Castiglioni; Daniela Parolaro
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

9.  CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.

Authors:  M Sabrina Spano; Liana Fattore; Gregorio Cossu; Serena Deiana; Paola Fadda; Walter Fratta
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

10.  Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse.

Authors:  Sara González; Marta Valenti; Rosario de Miguel; Filomena Fezza; Javier Fernández-Ruiz; Vincenzo Di Marzo; José A Ramos
Journal:  Br J Pharmacol       Date:  2004-09-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.